Immix Biopharma, Inc.
Immix Biopharma is a clinical-stage company developing CAR-T cell therapy NXC-201 for light chain amyloidosis and other serious diseases.
8-KSep 30Latest SEC filing
Sep 30Latest story
September 2026
July 2026
Sign inSign inImmix Biopharma is a clinical-stage company developing CAR-T cell therapy NXC-201 for light chain amyloidosis and other serious diseases.